Structure (Divalproex Sodium De Figure 1)
Chemical structure diagram of divalproex sodium showing its molecular components and bonding arrangement.*
Divalproex Sodium Tablet, Delayed Release
Product Images NDC 71335-2782
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 71335-2782). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure1 (Divalproex Sodium De Figure 2)
A bar chart comparing percentages for two studies labeled Study 1 (YMRS) and Study 2 (MRS). Each study shows two bars: one labeled PBO and the other DVPX. DVPX bars are higher, with 60% for Study 1 and 58% for Study 2, while PBO bars show 26% and 29% respectively.*
Figure2 (Divalproex Sodium De Figure 3)
A line graph comparing the percentage reduction in CPS rate between divalproex sodium and placebo across a patient population, with the x-axis representing the percentage of patients and the y-axis showing improvement or worsening of CPS rate.*
Figure3 (Divalproex Sodium De Figure 4)
A line graph depicting the percentage reduction in CPS rate relative to the percentage of patients. The graph compares high dose and low dose treatments, showing trends of improvement and worsening outcomes with corresponding dose levels.*
Figure4 (Divalproex Sodium De Figure 5)
A bar chart comparing placebo and divalproex sodium groups across two studies. The y-axis quantifies an unspecified variable, and the x-axis distinguishes Study 1 and Study 2, each showing results for placebo versus divalproex sodium treatment.*
Label (Lbl713352782)
Label for divalproex sodium delayed-release tablets, USP, 500 mg strength. The label shows the product is repackaged by Bryant Ranch Prepack in Burbank, CA, and manufactured by OrBion Pharmaceuticals Private Ltd. The package contains 60 tablets. The label includes storage instructions and QR codes for package insert and prescribing information.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
